Obermatt

Jubilant Life Sciences

NSI:JUBLPHARMA · INE700A01033
PharmaceuticalsMedium

360

47
EV / EBIT30
Price / Owner Earnings89
Owner Earnings Yield1
Dividend Yield43
Price/Sales75
EV / Gross Profit79
Price/Book64
Return on Capital61
Cash Return on Capital29
Return on Equity50
EBIT Margin40
Gross Profitability67
Cash Conversion83
Owner Earnings Margin18
Sales growth76
Profit Growth23
Long-Term EPS Growth54
Reinvestment4
Price momentum33
Debt load22
Refinancing27
Debt Payback1
Liquidity28
Analyst ratings100
Opinion Changes50
Price Target Upside28
Market mood49
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Jubilant Life Sciences clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryIndia
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeBSE
Founded1978
Employees751
Websitejubl.com
ISININE700A01033
Last UpdateApr 2, 2026
Index & Theme
Health DiagnosticsCardiovascularImmunologyOncologyCentral Nervous SystemAllergyLife SciencePharmaceutical

Description

Jubilant Pharmova Limited operates as an integrated pharmaceutical company that provides pharmaceuticals and healthcare services. The company engages in the manufacture and distribution of a diverse portfolio of products, including active pharmaceuti…

Analysis

Middle-of-the-road

Jubilant Pharmova Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
27
2023202420252026

All-time high

65

Jan 2025

All-time low

7

Jan 2023

Average rank

28

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
75
71
91
89
Price/Earnings
51
36
69
89
Price/Book
64
67
90
84
Dividend Yield
43
29
61
28
Value (overall)
68
55
83
81

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Jubilant Life Sciences with its peers
Zydus
NSI:ZYDUSLIFE
22
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Laurus Labs
NSI:LAURUSLABS
28
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Sun Pharmaceuticals
NSI:SUNPHARMA
55
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Theravance Biopharma
NMQ:TBPH
87
CountryCayman Islands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Inter Pharma
SET:IP
59
CountryThailand
IndustryPersonal Products
SizeSmall
Full Stock Analysis →
Dr. Reddy's
NSI:DRREDDY
29
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →